Search

Author/Creator Walling, David P.

1. A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia. Issue 4 (July 2019)

Authors:
DeMartinis, Nicholas; Lopez, Rene N.; Pickering, Eve H.; Schmidt, Christopher J.; Gertsik, Lev; Walling, David P.; Ogden, Adam
Journal:
Journal of clinical psychopharmacology
Issue:
Volume 39:Issue 4(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. (July 2019)

Authors:
Hard, Marjie L.; Wehr, Angela; von Moltke, Lisa; Du, Yangchun; Farwick, Sarah; Walling, David P.; Sonnenberg, John
Journal:
Therapeutic advances in psychopharmacology
Issue:
Volume 9(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit, Burden, and Satisfaction in Patients with Schizophrenia. (April 2021)

Authors:
Simmons, Adam; Carpenter-Conlin, Julia; Bessonova, Leona; O'Sullivan, Amy K.; McDonnell, David; Saucier, Cory; White, Michelle K.; Foster, April M.; Bjorner, Jakob B.; Lapeyra, Olga; Walling, David P.
Journal:
CNS spectrums
Issue:
Volume 26:Number 2(2021)
Page Start:
156
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗